We then applied this metagene to the World IBC Consortium tumor samples [6] and identified that untreated tumor samples from IBC patients compared to non-IBC and normal breast samples have a heightened expression of this NFκB pathway enriched signature [19, 20]. The gene discussed is NFKB1; the disease is neoplasm.